メディア掲載記事

​ICON will buy PRA Health Sciences for about $12 billion in cash and stock, snapping up one of the larger independent companies in the drugmaker services business.

In a cash and stock transaction value of approximately $12 billion, ICON plc has announced its acquisition of PRA Health Sciences as part of a focus on innovative and high- quality clinical trials.

ICON is set to acquire rival PRA Health Sciences in a $12 billion deal that will vault the combined company into second place among clinical trial services providers.

Angela Brown, Global Head and Senior Director, Regulatory Affairs and Nicole A. Cowan, Director, Project Management, IVD Operations & Strategy, examine how IVD manufacturers can meet 2022 deadlines despite the COVID-19 pandemic.

In this article, EB McLindon offers insights to help sponsors decide which approach is most optimal for a clinical trial.

Dr. Caroline Forkin discusses the current status of HIV treatments and potential for researchers to develop a vaccine.

Angela Brown, Global Head and Senior Director, Regulatory Affairs and Nicole Cowan, Director, Project Management, IVD Operations & Strategy, provide expert commentary on overcoming IVDR challenges for companion diagnostics.

ICON's Tamie Joeckel offers expert commentary on managing and executing CGT clinical trials.

Recruitment has begun in the UK for a world-first study to investigate whether using different COVID-19 vaccines for first and second doses is as effective as using the same type of vaccine for both. ICON’s Dr Garrett provides commentary.

ICON's Dr. Garrett comments on the UK government's new 'Com-Cov' study of over 800 patients, designed to test mixing doses of the Oxford and Pfizer COVID-19 vaccines, as well as different intervals between doses.